The advances in therapy of blastic plasmacytoid dendritic cell neoplasm

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405. PubMed PMID: 27069254.
   PubMed Web of Science ®Google Scholar
• Bueno C, Almeida J, Lucio P, et al. Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica. 2004;89:58–69. PubMed PMID: 14754607.
   PubMed Web of Science ®Google Scholar
• Riaz W, Zhang L, Horna P, et al. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Cancer Control. 2014;21:279–289. PubMed PMID: 25310209.
   PubMed Web of Science ®Google Scholar
• Wang S, Wang X, Liu M, et al. Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents. Ann Hematol. 2018;97:563–572. PubMed PMID: 29455234.
   PubMed Web of Science ®Google Scholar
• Julia F, Dalle S, Duru G, et al. Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol. 2014;38:673–680. PubMed PMID: 24441662.
   PubMed Web of Science ®Google Scholar
• Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98:239–246. PubMed PMID: 23065521; PubMed Central PMCID: PMCPMC3561431.
   PubMed Web of Science ®Google Scholar
• Swerdlow S, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008. p. 439.
   Google Scholar
• Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm. Hematolol Am Soc Hematol Educ Program. 2016;2016:16–23. PubMed PMID: 27913457.
   PubMedGoogle Scholar
• Martin-Martin L, Almeida J, Pomares H, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7:10174–10181. PubMed PMID: 26840087; PubMed Central PMCID: PMCPMC4891111.
   PubMed Web of Science ®Google Scholar
• Feuillard J, Jacob MC, Valensi F, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002;99:1556–1563. PubMed PMID: 11861268.
   PubMed Web of Science ®Google Scholar
• Reimer P, Rudiger T, Kraemer D, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32:637–646. PubMed PMID: 13130309.
   PubMed Web of Science ®Google Scholar
• Deotare U, Yee KW, Le LW, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-color flow cytometry diagnosis and hyperCVAD therapy. Am J Hematol. 2016;91:283–286. PubMed PMID: 26619305.
   PubMed Web of Science ®Google Scholar
• Tsagarakis NJ, Kentrou NA, Papadimitriou KA, et al. Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the hellenic dendritic cell leukemia study group. Leuk Res. 2010;34:438–446. PubMed PMID: 19793612.
   PubMed Web of Science ®Google Scholar
• Aoki T, Suzuki R, Kuwatsuka Y, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125:3559–3562. PubMed PMID: 25918345.
   PubMed Web of Science ®Google Scholar
• Alayed K, Patel KP, Konoplev S, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88:1055–1061. PubMed PMID: 23940084.
   PubMed Web of Science ®Google Scholar
• Hyakuna N, Toguchi S, Higa T, et al. Childhood blastic NK cell leukemia successfully treated with L-asparagenase and allogeneic bone marrow transplantation. Pediatr Blood Cancer. 2004;42:631–634. PubMed PMID: 15127419.
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim HJ, Kim SH, et al. Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea. Korean J Intern Med. 2017;32:890–899. PubMed PMID: 28870016; PubMed Central PMCID: PMCPMC5583450.
   PubMed Web of Science ®Google Scholar
• Gilis L, Lebras L, Bouafia-Sauvy F, et al. Sequential combination of high dose methotrexate and L-asparaginase followed by allogeneic transplant: a first-line strategy for CD4+/CD56+ hematodermic neoplasm. Leuk Lymphoma. 2012;53:1633–1637. PubMed PMID: 22260159.
   PubMed Web of Science ®Google Scholar
• Gruson B, Vaida I, Merlusca L, et al. L-asparaginase with methotrexate and dexamethasone is an effective treatment combination in blastic plasmacytoid dendritic cell neoplasm. Br J Haematol. 2013;163:543–545. PubMed PMID: 23937331.
   PubMed Web of Science ®Google Scholar
• Jegalian AG, Buxbaum NP, Facchetti F, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010;95:1873–1879. PubMed PMID: 20663945; PubMed Central PMCID: PMCPMC2966909.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Al Malki MM, Deotare U, et al. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Br J Haematol. 2017;179:781–789. PubMed PMID: 28980314.
   PubMed Web of Science ®Google Scholar
• Roos-Weil D, Dietrich S, Boumendil A, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European group for blood and marrow transplantation. Blood. 2013;121:440–446. PubMed PMID: 23203822.
   PubMed Web of Science ®Google Scholar
• Gurion R, Vidal L, Gafter-Gvili A, et al. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome–a systematic review and meta-analysis. Haematologica. 2010;95:303–310. PubMed PMID: 19773261; PubMed Central PMCID: PMCPMC2817034.
   PubMed Web of Science ®Google Scholar
• Laribi K, Denizon N, Ghnaya H, et al. Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine. Eur J Haematol. 2014;93:81–85. PubMed PMID: 24571716.
   PubMed Web of Science ®Google Scholar
• Khwaja R, Daly A, Wong M, et al. Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 cases. Leuk Lymphoma. 2016;57:2720–2722. PubMed PMID: 26984056.
   PubMed Web of Science ®Google Scholar
• Ulrickson ML, Puri A, Lindstrom S, et al. Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm. Am J Hematol. 2017;92:E75–E7. PubMed PMID: 28224664.
   PubMed Web of Science ®Google Scholar
• Krug LM, Ng KK, Kris MG, et al. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res. 2000;6:3493–3498. PubMed PMID: 10999734.
   PubMed Web of Science ®Google Scholar
• Arranto C, Tzankov A, Halter J. Blastic plasmacytoid dendritic cell neoplasm with transient response to pralatrexate. Ann Hematol. 2017;96:681–682. PubMed PMID: 28013360.
   PubMed Web of Science ®Google Scholar
• Leitenberger JJ, Berthelot CN, Polder KD, et al. CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate. J Am Acad Dermatol. 2008;58:480–484. PubMed PMID: 18280345.
   PubMed Web of Science ®Google Scholar
• Betrian S, Guenounou S, Luquet I, et al. Bendamustine for relapsed blastic plasmacytoid dendritic cell leukaemia. Hematol Oncol. 2017;35:252–255. PubMed PMID: 28620927.
   PubMed Web of Science ®Google Scholar
• Steinberg A, Kansal R, Wong M, et al. Good clinical response in a rare aggressive hematopoietic neoplasm: plasmacytoid dendritic cell leukemia with no cutaneous lesions responding to 4 donor lymphocyte infusions following transplant. Case Rep Transplant. 2011;2011:651906. PubMed PMID: 23198261; PubMed Central PMCID: PMCPMC3504287.
   PubMedGoogle Scholar
• Unteregger M, Valentin A, Zinke-Cerwenka W, et al. Unrelated SCT induces long-term remission in patients with blastic plasmacytoid dendritic cell neoplasm. Bone Marrow Transplant. 2013;48:799–802. PubMed PMID: 23208316.
   PubMed Web of Science ®Google Scholar
• Frankel AE, Ramage J, Kiser M, et al. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng. 2000;13:575–581. PubMed PMID: 10964987.
   PubMedGoogle Scholar
• Frankel AE, Hall PD, McLain C, et al. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. Bioconjug Chem. 1998;9:490–496. PubMed PMID: 9667951.
   PubMed Web of Science ®Google Scholar
• Frankel AE, Rossi P, Kuzel TM, et al. Diphtheria fusion protein therapy of chemoresistant malignancies. Curr Cancer Drug Targets. 2002;2:19–36. PubMed PMID: 12188918.
   PubMed Web of Science ®Google Scholar
• Jedema I, Barge RM, Frankel AE, et al. Acute myeloid leukemia cells in G0 phase of the cell cycle that are unresponsive to conventional chemotherapy are sensitive to treatment with granulocyte-macrophage colony-stimulating factor/diphtheria toxin fusion proteins. Exp Hematol. 2004;32:188–194. PubMed PMID: 15102480.
   PubMed Web of Science ®Google Scholar
• Angelot-Delettre F, Roggy A, Frankel AE, et al. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent. Haematologica. 2015;100:223–230. PubMed PMID: 25381130; PubMed Central PMCID: PMCPMC4803130.
   PubMed Web of Science ®Google Scholar
• Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124:385–392. PubMed PMID: 24859366; PubMed Central PMCID: PMCPMC4260361.
   PubMed Web of Science ®Google Scholar
• Pemmaraju NSK LA, Stein A, Vasu S, et al. Results of pivotal phase 2 trial of SL-401 in patients with blastic plasmacytoid dendritic cll neoplasm (BPDCN). Blood. 2017;130:1298.
   Web of Science ®Google Scholar
• Kovtun Y, Jones GE, Adams S, et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv. 2018;2:848–858. PubMed PMID: 29661755; PubMed Central PMCID: PMCPMC5916008.
   PubMed Web of Science ®Google Scholar
• Arcangeli S, Rotiroti MC, Bardelli M, et al. Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid Leukemia. Mol Ther. 2017;25:1933–1945. PubMed PMID: 28479045; PubMed Central PMCID: PMCPMC5542631.
   PubMed Web of Science ®Google Scholar
• Gill S, Tasian SK, Ruella M, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014;123:2343–2354. PubMed PMID: 24596416; PubMed Central PMCID: PMCPMC3983612.
   PubMed Web of Science ®Google Scholar
• Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia. 2014;28:1596–1605. PubMed PMID: 24504024.
   PubMed Web of Science ®Google Scholar
• Montero J, Stephansky J, Cai T, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discov. 2017;7:156–164. PubMed PMID: 27986708; PubMed Central PMCID: PMCPMC5296248.
   PubMed Web of Science ®Google Scholar
• Grushchak S, Joy C, Gray A, et al. Novel treatment of blastic plasmacytoid dendritic cell neoplasm: a case report. Medicine (Baltimore). 2017;96:e9452. PubMed PMID: 29390581; PubMed Central PMCID: PMCPMC5758283.
   PubMed Web of Science ®Google Scholar
• Agliano A, Martin-Padura I, Marighetti P, et al. Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res. 2011;17:6163–6173. PubMed PMID: 21856771.
   PubMed Web of Science ®Google Scholar
• Philippe L, Ceroi A, Bole-Richard E, et al. Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2017;102:1861–1868. PubMed PMID: 28798071; PubMed Central PMCID: PMCPMC5664390.
   PubMed Web of Science ®Google Scholar